rs11617740 (FGF14): Genetic Variant Overview

Key takeaways

• The studies sourced for this entry do not directly examine rs11617740 or the FGF14 (Fibroblast Growth Factor 14) gene.
• No associations, effect sizes, or drug-response annotations for this variant appear in the provided evidence.
• The sourced research covers infant gut microbiota genetics and a preeclampsia genome-wide association study, both involving loci unrelated to this variant.
• No lifestyle considerations are supported by the current source material.

What the research says

Neither study provided for this entry directly investigates rs11617740 or the FGF14 locus. The first study examined host genomic influences on infant gut microbiota within the context of childhood asthma and atopy in the CHILD Cohort Study, reporting genome-wide significant signals near the MARCO and SMAD2 genes rather than the FGF14 locus. The second study performed a genome-wide association study for preeclampsia across Afro-Caribbean, European ancestry, and Hispanic cohorts drawn from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, identifying candidate single nucleotide polymorphisms and copy-number variants - none of which reached Bonferroni-corrected significance and none of which correspond to this variant.

Reported associations

• Infant gut microbiota and childhood asthma and atopy: Variants near the MARCO gene were associated with reduced food and inhalant sensitization and with abundance of Blautia obeum at age 3 months (P = 9.4 × 10^-8, n = 779 infants). Variants near SMAD2 interacted with breastfeeding to influence a microbial network cluster associated with childhood asthma (P = 8.3 × 10^-8). These findings concern other loci and do not pertain to rs11617740.
• Preeclampsia (maternal genetics): Candidate SNPs were identified in Afro-Caribbean (21 cases / 1,049 controls), European ancestry (50 cases / 1,207 controls), and Hispanic (62 cases / 661 controls) cohorts; none reached Bonferroni-corrected genome-wide significance, and rs11617740 is not identified among any reported candidates.

Evidence quality

Neither of the two provided studies reports data on rs11617740 or the FGF14 locus. The gut microbiota study involved 770-779 infants across two time points and identified genome-wide significant signals only at loci unrelated to FGF14. The preeclampsia genome-wide association study was limited by modest case counts (21-62 per ethnic group) and explicitly acknowledged that no signal reached corrected significance across any ethnic group. Because no provided source addresses this variant directly, effect sizes, replication status, and p-values for rs11617740 cannot be reported, and the evidence base for this entry is absent.

Lifestyle considerations

No lifestyle considerations on file for this variant.